205 related articles for article (PubMed ID: 36273494)
1. SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
Llorca-Cardenosa MJ; Aronson LI; Krastev DB; Nieminuszczy J; Alexander J; Song F; Dylewska M; Broderick R; Brough R; Zimmermann A; Zenke FT; Gurel B; Riisnaes R; Ferreira A; Roumeliotis T; Choudhary J; Pettitt SJ; de Bono J; Cervantes A; Haider S; Niedzwiedz W; Lord CJ; Chong IY
Cancer Res; 2022 Nov; 82(21):3962-3973. PubMed ID: 36273494
[TBL] [Abstract][Full Text] [Related]
2. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.
O'Leary PC; Chen H; Doruk YU; Williamson T; Polacco B; McNeal AS; Shenoy T; Kale N; Carnevale J; Stevenson E; Quigley DA; Chou J; Feng FY; Swaney DL; Krogan NJ; Kim M; Diolaiti ME; Ashworth A
Cancer Res; 2022 Nov; 82(21):3950-3961. PubMed ID: 36273492
[TBL] [Abstract][Full Text] [Related]
3. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
[TBL] [Abstract][Full Text] [Related]
4. Cryo-EM structure of SMG1-SMG8-SMG9 complex.
Zhu L; Li L; Qi Y; Yu Z; Xu Y
Cell Res; 2019 Dec; 29(12):1027-1034. PubMed ID: 31729466
[TBL] [Abstract][Full Text] [Related]
5. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Durinikova E; Reilly NM; Buzo K; Mariella E; Chilà R; Lorenzato A; Dias JML; Grasso G; Pisati F; Lamba S; Corti G; Degasperi A; Cancelliere C; Mauri G; Andrei P; Linnebacher M; Marsoni S; Siena S; Sartore-Bianchi A; Nik-Zainal S; Di Nicolantonio F; Bardelli A; Arena S
Clin Cancer Res; 2022 Sep; 28(17):3874-3889. PubMed ID: 35881546
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction.
Ditano JP; Donahue KL; Tafe LJ; McCleery CF; Eastman A
Sci Rep; 2021 Mar; 11(1):7077. PubMed ID: 33782497
[TBL] [Abstract][Full Text] [Related]
7. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
[TBL] [Abstract][Full Text] [Related]
8. Structure of a SMG8-SMG9 complex identifies a G-domain heterodimer in the NMD effector proteins.
Li L; Lingaraju M; Basquin C; Basquin J; Conti E
RNA; 2017 Jul; 23(7):1028-1034. PubMed ID: 28389433
[TBL] [Abstract][Full Text] [Related]
9. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
10. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [
Carlucci G; Carney B; Sadique A; Vansteene A; Tang J; Reiner T
Nucl Med Biol; 2017 May; 48():9-15. PubMed ID: 28157626
[TBL] [Abstract][Full Text] [Related]
12. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
13. Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Ao W; Kim HI; Tommarello D; Conrads KA; Hood BL; Litzi T; Abulez T; Teng PN; Dalgard CL; Zhang X; Wilkerson MD; Darcy KM; Tarney CM; Phippen NT; Bakkenist CJ; Maxwell GL; Conrads TP; Risinger JI; Bateman NW
Gynecol Oncol; 2023 Oct; 177():60-71. PubMed ID: 37639904
[TBL] [Abstract][Full Text] [Related]
14. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
16. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
Buisson R; Boisvert JL; Benes CH; Zou L
Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
[TBL] [Abstract][Full Text] [Related]
17. Expanding the phenotypic and allelic spectrum of SMG8: Clinical observations reveal overlap with SMG9-associated disease trait.
Abdel-Salam GMH; Duan R; Abdel-Hamid MS; Sayed ISM; Jhangiani SN; Khan Z; Du H; Gibbs RA; Posey JE; Marafi D; Lupski JR
Am J Med Genet A; 2022 Feb; 188(2):648-657. PubMed ID: 34761517
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
[TBL] [Abstract][Full Text] [Related]
19. The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.
Bradbury A; Zenke FT; Curtin NJ; Drew Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954206
[TBL] [Abstract][Full Text] [Related]
20. Functionally-instructed modifiers of response to ATR inhibition in experimental glioma.
Walter B; Hirsch S; Kuhlburger L; Stahl A; Schnabel L; Wisser S; Haeusser LA; Tsiami F; Plöger S; Aghaallaei N; Dick AM; Skokowa J; Schmees C; Templin M; Schenke-Layland K; Tatagiba M; Nahnsen S; Merk DJ; Tabatabai G
J Exp Clin Cancer Res; 2024 Mar; 43(1):77. PubMed ID: 38475864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]